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ABSTRACT
Background. For a selection of patients with colorectal
liver metastases (CRLM), liver resection is a curative option.
In order to predict long-term survival, clinicopathologic risk
scores have been developed, but little is known about his-
tologic factors and their prognostic value for disease-free and
overall survival. The objective of the present study was to
assess possible prognostic histologic factors in patients with
solitary CRLM treated with liver resection who did not re-
ceive neoadjuvant treatment.
Methods. Patients with solitary CRLM who underwent
liver resection between 1992 and 2011 were evaluated for
clinical prognostic factors. Histologic analyses on tumor
thickness at the tumor–normal interface, presence of a fi-
brotic capsule, intrahepatic vascular invasion, lymphatic
invasion, or bile duct invasion and perineural growth were
performed, using immunohistochemistry.
Results. A total of 124 patients were analyzed with a
median follow-up of 41 months (range 1–232 months).
There was no association between histologic factors and
disease-free survival in multivariate analysis. In multi-
variate analysis, intrahepatic lymphatic invasion was
associated with a decreased overall survival (41.9 vs.
61.0 months; p = 0.041), especially in combination with
vascular invasion (n = 15) (28.1 vs. 62.2 months;
p\ 0.0001). In addition, size over 50 mm (29.2 vs.
65.9 months; p = 0.004) and interval less than 12 months
between resection of the primary tumor and diagnosis of
liver metastasis (49.0 vs. 91.5 months: p = 0.019) were
also independent adverse prognostic factors.
Conclusions. Intrahepatic lymphatic invasion, especially
in combination with vascular invasion, is an important
adverse prognostic factor for overall survival in patients
with solitary CRLM after liver resection.
Colorectal cancer is one of the leading causes of cancer
death worldwide as a result of its considerable risk of de-
velopment of metastases.1 When metastatic disease is
confined to the liver, partial liver resection is the only
curative therapeutic option, with 5-year overall survival
(OS) percentages between 20 and 60 %, depending on
patient and tumor characteristics.2–4 In order to explain
these varying survival rates, different clinicopathologic risk
scores have been developed. In many of these risk scores,
nodal status of the primary tumor, size and number of the
colorectal liver metastases (CRLM), disease-free interval
from treatment of the primary until detection of the CRLM,
and preoperative level of carcinoembryonic antigen (CEA)
are combined to predict long-term survival.5–9 These
scoring systems are relevant with respect to prediction of
survival, but to our knowledge, they have not been used for
risk stratification in controversial areas such as the ad-
ministration of neoadjuvant or adjuvant systemic therapy
or surveillance.
In primary colorectal cancer histologic factors such as
extramural venous invasion, perineural growth, lymphatic
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invasion, angioinvasion, and diffuse growth pattern have
been associated with poorer survival outcomes.10,11 Ex-
tramural venous invasion in particular is considered a poor
prognostic factor, and as a result, patients with extramural
venous invasion in stage II colon cancer are considered
candidates for adjuvant systemic treatment.12 Very little is
known about the impact of histologic features of colorectal
liver metastases on OS, as described in a recent review.13
Vascular invasion, bile duct invasion, or lymphatic in-
vasion by tumor cells in CRLM have all been suggested as
prognostic factors for long-term survival.5,14–23 Perineural
growth, the presence of a fibrous capsule, and tumor
thickness at the tumor–normal interface have also been
linked to survival in patients with CRLM.14,15,19,24–26
Variations in definitions and selection of patients have
limited the impact of these studies. Furthermore, none of
these previous studies has evaluated multiple histologic
factors of the liver resection specimens, in combination
with established risk scores in a homogenous group of
patients. Most studies included patients who underwent
neoadjuvant therapy as well as chemotherapy-naive pa-
tients, patients with multiple liver metastases, or patients
with extrahepatic disease.5,14–21,23,24 The results of these
previous studies might be biased because of the known
changes in histologic features observed in liver metastases
after systemic therapy, and the possible heterogeneous
nature of multiple metastases.27–30
The objective of the current study was to assess possible
prognostic histologic factors for long-term survival in pa-
tients with solitary colorectal liver metastases who
underwent a complete (R0) liver without neoadjuvant
systemic therapy.
MATERIALS AND METHODS
Patients
Patients were identified who underwent complete (R0)
liver resection for a solitary CRLM between 1992 and 2011
in a tertiary referral hospital. R0 resections were defined as
liver resections with clear resection margins in patients
who did not have evidence of disease in any other loca-
tions. Demographics and clinicopathologic factors with
regard to the primary tumor, as well as the liver metastasis,
were collected per patient. Special attention was given to
the four different items from the clinical risk score ac-
cording to Fong et al.: nodal status of the primary tumor;
preoperative CEA level and size of the metastasis, and
interval between resection of the primary tumor and diag-
nosis of CRLM.9 It is unknown whether systemic treatment
influences the presence of certain histopathology factors
and therefore patients who were treated with neoadjuvant
systemic therapy were excluded from the current study.
Patients who died from postoperative complications, de-
fined as within 30 days after liver resection, were also
excluded. Patients underwent follow-up according to our
current Dutch follow-up guidelines, with regular outpatient
visits, CEA testing and computed tomographic scans of
chest and abdomen.
Histopathology
R0 liver resection specimens with a solitary CRLM were
selected from the archive. Routine workup consisted of
sampling of macroscopically normal liver tissue, invasive
front of the metastasis, and additional tumor blocks, de-
pending on the size of metastasis. Slide revision was
performed independently by two investigators (JdR, NK).
Discrepancies were resolved by simultaneous reexamina-
tion of the slides by both investigators using a two-headed
microscope. In case of discrepancy, the senior pathologist
(IN) made the final call.
Tumor thickness at the tumor–normal interface was
determined in routine slides. Tumor–normal interface was
defined as the interface between tumor and normal liver
tissue, as described by Maru et al. and validated by oth-
ers.26,31,32 In all tumors, tumor thickness was measured
with a ruler at multiple foci, and maximum tumor thickness
was used and defined as uninterrupted layers of tumor cells
without admixed fibrotic stroma, acellular mucin, or non-
neoplastic liver parenchyma. The median tumor thickness
at tumor–normal interface was used to divide the patient
group in a group with a larger and a smaller layer of vital
tumor cells (Fig. 1).
The presence of a fibrotic capsule around the metastasis
was evaluated in routine slides. The fibrous tissue between
tumors and liver parenchyma was classified as absent (no
FIG. 1 Tumor thickness at tumor–normal interface; arrow indicates
correct measurement with uninterrupted layer of tumor cells. Original
magnification, 910
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fibrous tissue observed) or present: tumor was separated
from the liver parenchyma by several layers of collagen
bundles in histologic sections (Fig. 2).
Immunohistochemistry and Scoring Methods
Immunohistochemistry was performed as previously
described.33 Antibodies, clones, dilution, and retrieval
methods are summarized in Supplementary Table 1.
Perineural growth was defined as a nerve, identified by
S-100 staining, being surrounded by tumor cells for at least
three quarters of the circumference and was scored as being
present or absent (Fig. 3a).
Lymphatic invasion was defined as single tumor cells or
cell clusters visible within vessels that showed im-
munoreactivity for D2-40 but not for CD31. Lymphatic
invasion was scored as being present or absent (Fig. 3b).
Vascular invasion was defined as single tumor cells or cell
clusters visible within vessels that showed immunoreactivity
for CD31 but not for D2-40. It was scored as being present or
absent (Fig. 3c).
Bile duct invasion was defined as single tumor cells or
cell clusters (CK7 negative) visible within bile ducts that
showed immunoreactivity for CK7. It was also scored as
being present or absent (Fig. 3d).
Outcome
Primary outcomes were disease-free survival (DFS)
and OS. DFS was defined as the interval in months be-
tween liver resection and disease recurrence, death, or
last follow-up. OS was defined as the interval in months
between liver resection and death or date of last follow-
up.
Statistical Analysis
Pearson’s Chi square test was used to calculate corre-
lations between the various histologic features. Survival
curves were estimated by the Kaplan–Meier method and
compared by log rank testing. Multivariate analysis was
performed using Cox proportional hazard model, and
variables were included that were associated with survival
in univariate analysis with a p value of\0.10. SPSS sta-
tistical software, version 18.0 (IBM, Armonk, NY, USA)
was used for all statistical analysis. A p value of\0.05 was
considered statistically significant.
RESULTS
Patients
Between January 1992 and March 2011, a total of 383
patients underwent liver resection for metastatic disease.
After excluding patients with multiple metastases, 135
patients remained who were surgically treated (R0) for
solitary CRLM. Eleven patients were excluded because
they received neoadjuvant chemotherapy (n = 5), were
lost to follow-up (n = 2), or died within 30 days after
liver resection (n = 4). A total of 124 patients were
eligible to be included in the current study, 76 men
(61.3 %) and 48 women (38.7 %). Median age at time of
resection was 64 years (range 40–80 years). Liver
metastasis were detected at a median of 8.8 months
(range 0–82 months) after resection of the primary tumor.
Median size of the metastasis was 35 mm (range 10–
130 mm). Median follow-up was 41 months (range 1–
232 months). In the complete study population, median
DFS was 28 months (range 1–228 months) with a median
OS of 57 months (range 1–232 months) and a 5-year
survival of 48.1 %.
FIG. 2 a Colorectal liver metastasis without fibrous capsule.
Original magnification, 920. b Colorectal liver metastasis with
fibrous capsule (arrow). Original magnification, 920
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Histopathologic Tumor Features
Fibrous Capsule and Tumor Thickness In 34.4 % of
patients (n = 43), the liver metastasis was surrounded by a
fibrous capsule. Presence of a fibrous capsule was not
associated with DFS, but it was associated with an
improved OS of 109.3 months, versus 56.7 months in
patients without a fibrous capsule (p = 0.037). In
multivariate analysis, presence of a fibrous capsule was
not an independent risk factor for OS (Tables 1, 2).
Tumor thickness at tumor–normal interface varied be-
tween 0.1 and 7.2 mm, with a median of 3 mm, and was
not correlated with the size of the liver metastases
(p = 0.213). Although there was a significant association
of increased thickness with decreased outcome (both DFS
and OS) in univariate analysis, it was no longer significant
in multivariate analysis (Tables 1, 2).
Intrahepatic Spread Frequency of different forms of
intrahepatic invasion varied; perineural growth (n = 11;
8.9 %) and bile duct invasion (n = 11; 8.8 %) were both
relatively uncommon, whereas vascular and lymphatic
invasion were seen more frequently (n = 46; 37.1 %,
respectively n = 33; 26.6 %).
In univariate analysis, presence of bile duct invasion
was associated with improved OS (76.7 vs. 55.9 months;
p = 0.048), but this was not the case in multivariate ana-
lysis (p = 0.094). Presence of intrahepatic lymphatic
invasion was correlated with a decreased median OS (41.9
vs. 62.2 months, p = 0.013), which remained significant in
multivariate analysis (p = 0.041) (Supplementary Fig. 1a).
In the current study, no correlation between different
forms of intrahepatic spread or between any of the histo-
logic features and the various items of the clinical risk
score was observed. However, there was a correlation be-
tween presence of a fibrous capsule and absence of
intrahepatic vascular invasion (p = 0.014) and between
presence of a fibrous capsule and presence of intrahepatic
bile duct invasion (p = 0.013).
In 15 patients, a combination of intrahepatic lymphatic
invasion and intrahepatic vascular invasion was present,
and this combination was associated with a decreased OS
(median 28.1 vs. 62.2 months) in univariate and multi-
variate analysis (p\ 0.0001) (Supplementary Fig. 1b).
FIG. 3 Different forms of intrahepatic invasion by tumor cells. a Perineural growth showing S-100 reactivity. b Lymphatic invasion showing
D2-40 reactivity. c Vascular invasion showing CD-31 reactivity. d Bile duct invasion showing CK-7 reactivity. Original magnification, 920
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DISCUSSION
The current study describes the association between
multiple histologic features in combination with clinical
factors and survival in 124 patients who underwent liver
resection for CRLM. A homogenous group of patients was
evaluated because all patients underwent a complete re-
section (R0), for a solitary metastasis without neoadjuvant
systemic treatment. The only significant histologic factor
associated with decreased survival in multivariate analysis
was presence of intrahepatic lymphatic invasion, especially
in combination with intrahepatic vascular invasion.
Other authors also described lymphatic invasion as a
negative predictor for survival.13,18,20 In the current study,
we observed a relative high frequency of lymphatic in-
vasion (26.6 %) compared to earlier studies (12–
15 %).18,20 This might be due to the use of immunohis-
tochemistry, which is supported by a recently published
study with the same methodology and a similar frequency
of lymphatic invasion (29 %).18,20,34–36 Presence of
TABLE 1 Relation of clinical and histologic factors with DFS after liver resection in patients with solitary CRLM
n % Median DFS UV p value MV p value
Size (mm)
B50 93 75 50.1 0.002* 0.020*
[50 31 25 14.5
CEA (ng/ml)
B200 121 97.6 27.5 0.508 –
[200 3 2.4 40.6
DFI (months)
B12 72 58.1 27.8 0.232 –
[12 52 41.9 25.4
Nodal state primary
N0 54 43.5 35.7 0.446
N? 70 56.5 27.5 –
Adjuvant therapy
No 106 85.5 20.2 0.013* 0.025*
Yes 18 14.5 [50
Tumor thickness at TNI (mm)
B3 60 48.4 [51 0.023* 0.118
[3 64 51.6 19.4
Fibrous capsule
Present 43 34.4 27.8 0.468 –
Absent 81 65.6 25.8
Perineural growth
Present 11 8.9 50.2 0.539 –
Absent 113 91.1 27.5
Vascular invasion
Present 46 37.1 18.0 0.055 0.287
Absent 78 62.9 40.8
Lymphatic invasion
Present 33 26.6 19.4 0.280 –
Absent 91 73.4 29.2
Bile duct invasion
Present 11 8.8 27.8 0.624 –
Absent 113 91.2 27.5
DFS disease-free survival, CRLM colorectal liver metastases, UV univariate, MV multivariate, CEA carcinoembryonic antigen, DFI disease-free
interval between treatment of primary tumor and detection of the CRLM, TNI tumor–normal interface
* p\ 0.05 was considered statistically significant
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lymphatic invasion has been associated with spread to
hepatic lymph nodes, which often leads to incurable dis-
ease.20,37 In the current study, the worse prognosis was
demonstrated in patients with a combination of vascular
and lymphatic invasion. This unfavorable combination has
been observed before and might reflect a tumor with
aggressive behavior.23
Another interesting finding from the current study was
that the median tumor thickness at tumor–normal interface
in patients who were not treated with neoadjuvant systemic
therapy was 3.0 mm. This was only slightly higher than the
tumor thickness of 2.8 mm described in patients treated
with neoadjuvant chemotherapy.26 This raises the question
whether tumor thickness at tumor–normal interface reflects
chemotherapy response or tumor biology; this would be an
interesting subject for further research.
A major strength of the present study is the inclusion of
patients with solitary CRLM only, who were operated with
complete margins (R0) to create an homogenous group of
patients. Previous studies on histologic prognostic factors
included patients with multiple CRLM and R1 resections
as well, which might lead to significant bias of the re-
sults.18,20,36 First, heterogeneity of histologic features
between the different liver metastases might exist and
could lead to bias studying prognostic factors for survival.
Second, patients who undergo R1 resection usually have a
higher risk of local recurrences and have an impaired
survival.38,39 Third, patients with multiple metastases have
a significantly decreased survival, and number of metas-
tases is the most important factor in the Fong classification
for survival.9 By excluding these potential biases in the
present study, the assessment of the prognostic histologic
factors are more reliable.
Another strength is that this homogenous group of pa-
tients with solitary metastasis were not treated with
neoadjuvant systemic therapy. In recent studies, patients
with and without neoadjuvant systemic therapy were
mixed, and conclusions were drawn from a population
highly susceptible to bias.25,36,40 Neoadjuvant systemic
therapy has a significant impact on tumor histology, and
even prognostic factors such as resection margins might be
less important.27,28,41 Because the detection of histologic
prognostic factors in metastatic disease is still in its infancy
and the effects of neoadjuvant systemic therapy on lym-
phatic invasion are unknown, a study with an homogeneous
population should be a first step. However, there seems to
be an increasing preference to utilize neoadjuvant systemic
therapy for high risk patients, despite a lack of convincing
evidence on survival benefit in patients with limited
metastases.42–44 Therefore, a limitation of the present study
is that the impact of lymphatic invasion on survival has to
be confirmed in patients treated with neoadjuvant systemic
therapy. In the total group of patients treated in our insti-
tution only 5 patients (3.8 %) with solitary metastasis were
treated with neoadjuvant chemotherapy, which made it
impossible to compare, but this should be the goal for fu-
ture research.
In conclusion, intrahepatic lymphatic invasion, based on
immunohistochemical detection of lymphatic vessels, is an
adverse prognostic factor for OS in patients with a solitary
TABLE 2 Relation of clinical and histologic factors with OS after
liver resection in patients with solitary CRLM
n % Median
OS
UV p
value
MV p
value
Size (mm)
B50 93 75 65.9 0.050* 0.004*
[50 31 25 29.2
CEA (ng/ml)
B200 121 97.6 57.3 0.912 –
[200 3 2.4 28.9
DFI
B12 72 58.1 49.0 0.059 0.019*
[12 52 41.9 91.5
Nodal state primary
N0 54 43.5 61.0 0.231 –
N? 70 56.5 44.6
Adjuvant therapy
No 106 85.5 57.2 0.955 –
Yes 18 14.5 29.2
Tumor thickness at TNI (mm)
B3 60 48.4 95.3 0.043* 0.068
[3 64 51.6 48.8
Fibrous capsule
Present 43 34.4 109.3 0.037* 0.240
Absent 81 65.6 56.7
Perineural growth
Present 11 8.9 109.3 0.652 –
Absent 113 91.1 55.9
Vascular invasion
Present 46 37.1 48.8 0.483 –
Absent 78 62.9 58.2
Lymphatic invasion
Present 33 26.6 41.9 0.013* 0.041*
Absent 91 73.4 62.2
Bile duct invasion
Present 11 8.8 76.7 0.048* 0.094
Absent 113 91.2 55.9
OS overall survival, CRLM colorectal liver metastases, UV univariate,
MV multivariate, CEA carcinoembryonic antigen, DFI disease-free
interval between treatment of primary tumor and detection of the
CRLM, TNI tumor–normal interface
* p\ 0.05 was considered statistically significant
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CRLM. Therefore, we recommend evaluating the presence
or absence of intrahepatic lymphatic and vascular invasion
in the histologic assessment of CRLM. Future research is
needed to determine whether adjuvant treatment strategies
should be based on these adverse prognostic histologic
factors.
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